Current Oncology (May 2023)

The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895

  • Maureen Trudeau,
  • Brent Fraser

DOI
https://doi.org/10.3390/curroncol30050380
Journal volume & issue
Vol. 30, no. 5
pp. 5047 – 5049

Abstract

Read online

CADTH read with interest the commentary published on 16 December 2022, entitled “Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain” [...]

Keywords